Trial · NCT00359138
The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)
NCT00359138, Phase 4, Completed, Organon and Co; results first posted 2010-11-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441). Trials, record NCT00359138. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00359138
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)
- NCT number
- NCT00359138
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 36 participants, actual
- Lead sponsor
- Organon and Co
- Conditions
- Hypersensitivity
- Interventions
- desloratadine, levocetirizine, Desloratadine placebo tablet, Levocetirizine placebo capsule
- First posted
- 2006-08-01
- Last updated
- 2022-02-09
- Results first posted
- 2010-11-01
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment | Starting at Day 8 | The number of days after treatment discontinuation until a measurable wheal and flare response. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment | Starting at Day 8 | Days | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 5 | Standard Error 1.65 | Days | |
| Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 4 | Standard Error 1.60 | Days | |
| Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | NA | Standard Error NA | Days |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 12 | |
| Overall Study | STARTED | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 12 | |
| Overall Study | STARTED | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | 12 | |
| Overall Study | COMPLETED | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 12 | |
| Overall Study | COMPLETED | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 12 | |
| Overall Study | COMPLETED | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | 12 | |
| Overall Study | NOT COMPLETED | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 0 | |
| Overall Study | NOT COMPLETED | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 0 | |
| Overall Study | NOT COMPLETED | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | 0 |
Source ClinicalTrials.gov
Adverse events42
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain Upper | Gastrointestinal disorders | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 1 | 12 | 1 |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 0 | 12 | 0 |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | 0 | 12 | 0 |
| other | Dry Mouth | Gastrointestinal disorders | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 0 | 12 | 0 |
| other | Dry Mouth | Gastrointestinal disorders | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 1 | 12 | 1 |
| other | Dry Mouth | Gastrointestinal disorders | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | 0 | 12 | 0 |
| other | Nausea | Gastrointestinal disorders | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 1 | 12 | 1 |
| other | Nausea | Gastrointestinal disorders | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 1 | 12 | 1 |
| other | Nausea | Gastrointestinal disorders | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | 0 | 12 | 0 |
| other | Vomiting | Gastrointestinal disorders | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 0 | 12 | 0 |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | ||
| Total, all-cause mortality | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | ||
| Total, all-cause mortality | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | ||
| Total, other adverse events | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 5 | 12 |
| Total, other adverse events | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 4 | 12 |
| Total, other adverse events | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | 1 | 12 |
| Total, serious adverse events | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | 0 | 12 |
| Total, serious adverse events | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | 0 | 12 |
| Total, serious adverse events | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | 0 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00359138
GET https://conductscience.org/api/trials/v1/NCT00359138/events?page=2